Those holding ABBV might want to look at an article quoting the CEOs of Novartis and Pfizer. It points out how difficult it has become to rely on the old-fashioned blockbuster drug concept, and how difficult it will be going forward for drug companies to continue to generate the huge revenue flows of the past. If you want to understand better the hurdles ahead for ABBV, search on NVS or PFE and check the recent articles listed. The headline says something about Novartis CEO. I worked for GSK for 20 years in research, and I think the perspective is valid.